Press Releases AstraZeneca PLC Deutsche Boerse AG

Equities

ZEG

GB0009895292

Real-time Estimate Tradegate Other stock markets 10:21:33 2024-07-16 EDT			5-day change	1st Jan Change
143.8 ^EUR	-0.16%		+0.81%	+17.36%

07-15	Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...
07-15	AstraZeneca: acquisition of Amolyt Pharma finalized	CF

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AstraZeneca : Acquisition of Amolyt Pharma completed Form 6 K	07-15	PU
AstraZeneca : Acquisition of Amolyt Pharma completed	07-15	PU
Selkirk Pharma, Inc. - Colleen Dixon Appointed CEO	07-10	AQ
Non-Hodgkin Lymphoma Pipeline 2024 \| Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences	07-09	AQ
Metastatic Renal Cell Carcinoma Pipeline 2024 \| AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics	07-09	AQ
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series a Cumulative Redeemable Perpetual Preferred Stock	07-08	AQ
Astrazeneca - Tagrisso with the addition of chemotherapy approved in the EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer	07-08	AQ
BenevolentAI - Leadership team change	07-04	AQ
Astrazeneca - Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer	07-02	AQ
Astrazeneca - Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention	07-02	AQ
AstraZeneca : Transparency Directive Form 6 K	07-01	PU
AstraZeneca : Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer Form 6 K	07-01	PU
Astrazeneca - Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer	06-27	AQ
Astrazeneca - IMFINZI demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial	06-26	AQ
Astrazeneca - Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer	06-26	AQ
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial	06-25	BU
AstraZeneca : Update on Imfinzi ADJUVANT BR.31 trial	06-25	PU
AstraZeneca : Imfinzi improved EFS and OS in bladder cancer	06-25	PU
Astrazeneca - Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer	06-19	AQ
Squamous Cell Carcinoma Pipeline 2024 \| FDA Approvals, Clinical Trials, Therapies, MOA, ROA \| Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna	06-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm